BeiGene

BeiGene Ltd. is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

CAMBRIDGE, Mass., & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces acceptance of a supplemental New Drug Application in China for BRUKINSA in Waldenström's macroglobulinemia based on the ASPEN trial.

BeiGene Announces Acceptance of a Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Waldenström's Macroglobulinemia

The stock price of BeiGene (NASDAQ: BGNE), a China-based biotechnology company focused on developing molecularly targeted and immuno-oncology drug candidates, has seen a fall of 15% over the last twenty-one trading days, while it is up 5% over the last week.

Will BeiGene Stock Rebound After A 15% Fall Over The Last Month?

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #JPMconference--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global science-driven biotechnology company, today announced that the Company will participate in the J.P. Morgan 40th Annual Healthcare Conference on Tuesday, January 11, 2022 at 5:15 p.m. ET. A live webcast can be accessed from the investors section of BeiGene's website at http://ir.beigene.com or http://hkexir.beigene.com. An archived replay will be available for 90 days following the event

BeiGene to Present at the J.P. Morgan 40th Annual Healthcare Conference

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the China National Medical Products Administration (NMPA) has approved BeiGene's anti-PD-1 antibody tislelizumab as a second- or third-line treatment for patients with locally advanced or metastatic non-small cell

China NMPA Approves Tislelizumab as Second- or Third-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Repligen

Sarepta Therapeutics

Here we present three biotech companies, which are likely to perform well in 2022, backed by strong fundamentals.

3 Biotech Stocks Worth Adding to Your Portfolio Next Year

I-Mab

In these troubled times of U.S.-China tensions, sometimes being a copycat has its benefits. The vast majority of the many publicly listed drug makers in China are essentially copycats that license mature drugs from other, mostly western, developers to sell in China.

As U.S. Takes Aim At China Drug Makers, Innovators Appear At Biggest Risk

Novartis

Novartis (NVS) signs collaboration and license agreement with BeiGene for ociperlimab (BGB-A1217), expanding research and development activities in immuno-oncology.

Novartis (NVS) Collaborates With BeiGene for Oncology Drug

BeiGene Ltd (NASDAQ: BGNE) announced an option, collaboration, and license agreement with Novartis AG (NYSE: NVS) to develop, manufacture, and commercialize BeiGene's ociperlimab in North America, Europe, and Japan.  Ociperlimab is currently being investigated in two global Phase 3 trials, the AdvanTIG-301 and AdvanTIG-302 trials, combined with tislelizumab in lung cancer.

Novartis Inks Option Agreement For BeiGene Anti-Cancer Therapy For Over $1 Billion

BeiGene Ltd. BGNE, +0.25% said Monday it had entered an agreement with Swiss drug company Novartis Pharma AG NVS, -0.20% to develop its investigational TIGIT inhibitor ociperlimab in North America, Europe, and Japan and to market five Novartis oncology treatments in China.

BeiGene to receive up to $1 billion in oncology deal with Novartis

Basel, December 20, 2021 — Novartis announced today the signing of an option, collaboration and license agreement with BeiGene, Ltd. for ociperlimab (BGB-A1217), expanding the company's research and development activities in immuno-oncology. Ociperlimab is a late-stage TIGIT inhibitor, a novel class of anti-cancer therapies that blocks the TIGIT protein receptor. Ociperlimab is currently being evaluated in two Phase III lung cancer trials and additional studies are ongoing in a wide range of solid tumors.

Novartis strengthens immunotherapy pipeline with option, collaboration and license agreement with BeiGene for TIGIT inhibitor ociperlimab

BASEL, Switzerland & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene expands collaboration with Novartis to develop and commercialize its TIGIT inhibitor and market five Novartis oncology medicines in China.

BeiGene Expands Collaboration with Novartis to Develop and Commercialize BeiGene's TIGIT Inhibitor and Market Five Novartis Oncology Medicines in China Broad Markets

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces the official launch of the BeiGene Bioisland Innovation Center (BIC), an innovator-centric incubator in Guangzhou, China.

BeiGene Announces Launch of Bioisland Innovation Center

Zai Lab Ltd.

The threat of a forced delisting is weighing heavily on these two Chinese biotech stocks.

Why Shares of BeiGene and Zai Lab Are Tanking Today

Wuxi Biologics Cayman Inc

The declines come after the Financial Times reported that the U.S. Commerce Department on Thursday is expected to place some Chinese companies involved in biotechnology on its entity list, which is designed to limit access to key U.S. exports.

Hong Kong-Listed Chinese Biotech Stocks Slide on U.S. Sanction Fears

BASEL, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces authorisation of BRUKINSA (zanubrutinib) for the treatment of adults with Waldenström's macroglobulinemia in Great Britain.

BeiGene Announces Authorisation of BRUKINSA (zanubrutinib) from the United Kingdom's MHRA for the Treatment of Adults with Waldenström's Macroglobulinemia in Great Britain

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that it has completed its previously announced initial public offering (STAR Offering) on the Science and Technology Innovation Board (STAR Market) of the Shanghai Stock Exchange (SSE). The shares offered in the

BeiGene Announces Closing of Its RMB22.2 Billion (US$3.5 Billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China

Chinese biotech company BeiGene Ltd opened lower on its Shanghai debut on Wednesday after raising over $3 billion in the biggest STAR Market listing this year.

Chinese biotech company BeiGene opens lower on Shanghai debut

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--Nanjing Leads Biolabs and BeiGene Announce Worldwide License and Collaboration Agreement for LBL-007 Anti-LAG-3 Antibody

Nanjing Leads Biolabs and BeiGene Announce Worldwide License and Collaboration Agreement for LBL-007 Anti-LAG-3 Antibody; BeiGene Granted Exclusive Commercialization Rights Outside of China

Baidu

New Oriental Education & Technology Group

iQIYI

Momo

TAL Education Group

Trip.com

Yum China Hlds

The U.S.-listed Chinese stocks with the most American ownership don't include many of the big names familiar to Wall Street, according to Morgan Stanley.

Here are the 10 U.S.-listed Chinese stocks with the greatest American ownership — and Alibaba's not one of them

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene presents results from Phase 3 SEQUOIA trial of BRUKINSA (zanubrutinib) in first-line chronic lymphocytic leukemia at the 63rd ASH meeting.

BeiGene Presents Results from SEQUOIA Trial of BRUKINSA (zanubrutinib) in First-Line Chronic Lymphocytic Leukemia at the 63rd ASH Annual Meeting

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene presents updated safety and efficacy findings on BRUKINSA (zanubrutinib) in patients with B-Cell Malignancies intolerant to BTK inhibitors.

BeiGene Presents Updated Safety and Efficacy Findings on BRUKINSA (zanubrutinib) in BTK Inhibitor-Intolerant Patients with Relapsed or Refractory B-Cell Malignancies

BeiGene Ltd (NASDAQ: BGNE) revealed the detailed data from the Phase 3 RATIONALE 309 trial of tislelizumab for nasopharyngeal cancer. The trial evaluated tislelizumab versus placebo combined with chemotherapy as a first-line treatment for recurrent or metastatic nasopharyngeal cancer.

BeiGene Unveils Results From Late-Stage Tislelizumab In Nasopharyngeal Cancer

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene presents data on tislelizumab in combination with chemotherapy in first-line recurrent or metastatic nasopharyngeal cancer at ESMO I-O 2021.

BeiGene Presents Results from Phase 3 Trial of Tislelizumab in Nasopharyngeal Cancer at ESMO Immuno-Oncology Congress 2021

The China National Medical Products Administration has approved BeiGene Ltd (NASDAQ: BGNE) / EUSA Pharma (UK) Ltd's Sylvant (siltuximab) for adult patients with multicentric Castleman disease (MCD), also known as idiopathic MCD (iMCD). The approval covers patients who are human immunodeficiency virus (HIV) negative and human herpes virus-8 (HHV-8) negative.

BeiGene - EUSA Pharma's Siltuximab Approved In China For Multicentric Castleman Disease

CAMBRIDGE, Mass. & BEIJING & HEMEL HEMPSTEAD, England--(BUSINESS WIRE)--BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT® (Siltuximab for Injection) in China for Idiopathic Multicentric Castleman Disease

News for BeiGene Stock (BGNE)